The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp
Open accessAbstract
This study was prospectively designed to evaluate a phase II study of gefitinib for non-small-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations. Clinical samples were tested for EGFR mutations by peptide nucleic acid-locked nucleic acid PCR clamp, and patients having EGFR mutations were given gefitinib 250 mg daily as the second treatment after chemotherapy. Poor PS patients omitted chemotherapy. Of 107 consecutive patients enrolled, samples from 100 patients were informative, and EGFR mutations were observed in 38 patients. Gefitinib was given to 27 patients with EGFR mutations, and the response rate was 78% (one complete response and 20 partial responses; 95% confidence interval: 58-93%). Median time to progression and median survival time (MST) from gefitinib treatment were 9.4 and 15.4 months, respectively. Grade 3 hepatic toxicity and skin toxicity were observed in one patient each. There were significant differences between EGFR mutations and wild-type patients in response rates (78 vs 14%, P = 0.0017), and MST (15.4 vs 11.1 months, P = 0.0135). A Cox proportional hazards model indicated that negative EGFR mutation was a secondary prognostic factor (hazards ratio: 2.259, P = 0.036). This research showed the need for screening for EGFR mutations in NSCLC patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The discovery of EGFR mutations and the dramatic responses observed with EGFR TKIs in retrospective and small phase II studies [20, 61, 62] paved the way to a paradigm shift in the clinical trial design, favoring the development of clinically and then molecularly selected studies in NSCLC.”
From A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives (2015) · cites this paper as [62]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J., Nishiwaki, Y., Vansteenkiste, J., Kudoh, S., Rischin, D., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.038 · Cited by 2,871
Kris, M. G., Natale, R. B., Herbst, R. S., Lynch, Jr., Prager, D., Belani, C. P., Schiller, J. H., Kelly, K., Spiridonidis, H., Sandler, A., et al. (2003) · JAMA · doi:10.1001/jama.290.16.2149 · Cited by 2,517
Thatcher, N., Chang, A., Parikh, P., Rodrigues Pereira, J., Ciuleanu, T., von Pawel, J., Thongprasert, S., Tan, E. H., Pemberton, K., Archer, V., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67625-8 · Cited by 2,079
Mitsudomi, T., Kosaka, T., Endoh, H., Horio, Y., Hida, T., Mori, S., Hatooka, S., Shinoda, M., Takahashi, T., & Yatabe, Y. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.992 · Cited by 940
Riely, G. J., Pao, W. J., Ceppa, D. P., Li, A. R., Rizvi, N. A., Venkatraman, E. S., Zakowski, M. F., Kris, M. G., Ladanyi, M., & Miller, V. A. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1846 · Cited by 730
Takano, T., Ohe, Y., Sakamoto, H., Tsuta, K., Matsuno, Y., Tateishi, U., Yamamoto, S., Nokihara, H., Yamamoto, N., Sekine, I., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.0793 · Cited by 696
Pao, W. J., & Miller, V. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.799 · Cited by 637
Bell, D. W., Lynch, T. J., Haserlat, S. M., Harris, P. L., Okimoto, R. A., Brannigan, B. W., Sgroi, D. C., Muir, B., Riemenschneider, M. J., Iacona, R. B., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.7078 · Cited by 598
Cited by
Sorted by citations
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525
Self-citationTravis, W. D., Brambilla, E. M., Noguchi, M., Nicholson, A. G., Geisinger, K. R., Yatabe, Y., Beer, D. G., Powell, C. A., Riely, G. J., Schil, P. E. V., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318206a221 · Cited by 4,834
Fukuoka, M., Wu, Y.-L., Thongprasert, S., Sunpaweravong, P., Leong, S.-S., Sriuranpong, V., Chao, T.-Y., Nakagawa, K., Chu, D.-T., Saijo, N., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.4235 · Cited by 1,581
Lindeman, N. I., Cagle, P. T., Beasley, M. B., Chitale, D. A., Dacic, S., Giaccone, G., Jenkins, R. B., Kwiatkowski, D. J., Saldivar, J.-S., Squire, J., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318290868f · Cited by 1,280
Azzoli, C. G., Baker, S., Temin, S., Pao, W., Aliff, T., Brahmer, J., Johnson, D. H., Laskin, J. L., Masters, G., Milton, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.5622 · Cited by 915
Yasuda, H., Kobayashi, S., & Costa, D. B. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70129-2 · Cited by 610
Inoue, A., Kobayashi, K., Maemondo, M., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mds214 · Cited by 540
Self-citationThird-generation EGFR and ALK inhibitors: mechanisms of resistance and management
Cooper, A. J., Sequist, L. V. D., & Lin, J. J. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00639-9 · Cited by 544
Inoue, A., Kobayashi, K., Usui, K., Maemondo, M., Okinaga, S., Mikami, I., Ando, M., Yamazaki, K., Saijo, Y., Gemma, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.7658 · Cited by 505
Self-citationLindeman, N. I., Cagle, P. T., Beasley, M. B., Chitale, D. A., Đačić, S., Giaccone, G., Jenkins, R. B., Kwiatkowski, D. J., Saldivar, J., Squire, J. A., et al. (2013) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2013.03.001 · Cited by 461
Nguyen, K.-S. H., Kobayashi, S., & Costa, D. B. (2009) · Clinical Lung Cancer · doi:10.3816/clc.2009.n.039 · Cited by 437
Lindeman, N. I., Cagle, P. T., Beasley, M. B., Chitale, D. A., Đačić, S., Giaccone, G., Jenkins, R. B., Kwiatkowski, D. J., Saldivar, J., Squire, J. A., et al. (2013) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2012-0720-oa · Cited by 426
Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond
Ladanyi, M., & Pao, W. J. (2008) · Modern Pathology · doi:10.1038/modpathol.3801018 · Cited by 374
Structure and Clinical Relevance of the Epidermal Growth Factor Receptor in Human Cancer
Kumar, A., Petri, E. T., Halmos, B., & Boggon, T. J. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.1178 · Cited by 308
Consensus for EGFR Mutation Testing in Non-small Cell Lung Cancer: Results from a European Workshop
Pirker, R., Herth, F. J. F., Kerr, K. M., Filipits, M., Tarón, M., Gandara, D. R., Hirsch, F. R., Grunenwald, D. H., Popper, H., Smit, E. F., et al. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181f1c8de · Cited by 283
Yang, C.-H., Yu, C., Shih, J., Chang, Y., Hu, F., Tsai, M.-C., Chen, K., Lin, Z., Huang, C.-J., Shun, C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.6695 · Cited by 238
Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC
Linardou, H., Dahabreh, I. J., Bafaloukos, D. I., Kosmidis, P., & Murray, S. J. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.62 · Cited by 236
Noninvasive Detection of EGFR T790M in Gefitinib or Erlotinib Resistant Non–Small Cell Lung Cancer
Kuang, Y., Rogers, A. M., Yeap, B. Y., Wang, L., Makrigiorgos, M. G., Vetrand, K., Thiede, S., Distel, R. J., & Janne, P. A. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2592 · Cited by 232
Ogino, A., Kitao, H., Hirano, S., Uchida, A., Ishiai, M., Kozuki, T., Takigawa, N., Takata, M., Kiura, K., & Tanimoto, M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0681 · Cited by 194
Morita, S., Okamoto, I., Kobayashi, K., Yamazaki, K., Asahina, H., Inoue, A., Hagiwara, K., Sunaga, N., Yanagitani, N., Hida, T., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0391 · Cited by 188
Self-citationFrequency of and variables associated with the EGFR mutation and its subtypes
Tanaka, T., Matsuoka, M., Sutani, A., Gemma, A., Maemondo, M., Inoue, A., Okinaga, S., Nagashima, M., Oizumi, S., Uematsu, K., et al. (2009) · International Journal of Cancer · doi:10.1002/ijc.24746 · Cited by 183
Self-citationPooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer
Takeda, M., Okamoto, I., & Nakagawa, K. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.01.026 · Cited by 182
Russo, A., Franchina, T., Rita Ricciardi, G. R., Picone, A., Ferraro, G., Zanghì, M., Toscano, G., Giordano, A., & Adamo, V. (2015) · Oncotarget · doi:10.18632/oncotarget.4254 · Cited by 173
Pragmatic issues in biomarker evaluation for targeted therapies in cancer
Gramont, A. D. E., Watson, S., Ellis, L. M., Rodon, J. A., Tabernero, J. M., de Gramont, A., & Hamilton, S. R. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.202 · Cited by 179
Costa, D. B., Kobayashi, S., Tenen, D. G., & Huberman, M. S. (2007) · Lung Cancer · doi:10.1016/j.lungcan.2007.05.017 · Cited by 160
Personalized medicine in lung cancer: what we need to know
Mok, T. S. K. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.126 · Cited by 165
Han, J., Lee, S.-H., Yoo, N. J., Hyung, L. S., Moon, Y. J., Yun, T., Kim, H. T., & Lee, J. S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2525 · Cited by 159
Maemondo, M., Minegishi, Y., Inoue, A., Kobayashi, K., Harada, M., Okinaga, S., Morikawa, N., Oizumi, S., Tanaka, T., Isobe, H., et al. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318260de8b · Cited by 155
Self-citationHammerman, P. S., Janne, P. A., & Johnson, B. E. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0189 · Cited by 147
Clinical outcomes in non‐small‐cell lung cancer patients with EGFR mutations: pooled analysis
Paz-Ares, L. G., Soulières, D., Melezínek, I., Moecks, J., Keil, L., Mok, T. S. K., Rosell, R., & Klughammer, B. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00991.x · Cited by 141
Petrelli, F., Borgonovo, K., Cabiddu, M., & Barni, S. (2012) · Clinical Lung Cancer · doi:10.1016/j.cllc.2011.08.005 · Cited by 141
Kamel, H. F. M., & Al-Amodi, H. S. A. B. (2017) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2016.11.005 · Cited by 137
Gridelli, C., de Marinis, F., Maïo, M. D., Cortinovis, D. L., Cappuzzo, F., & Mok, T. S. K. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2010.12.008 · Cited by 133
Zhu, J., Zhong, W., Zhang, G.-C., Li, R., Zhang, X., Guo, A., Zhang, Y.-F., An, S., Mok, T. S. K., & Wu, Y.-L. L. C. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.02.064 · Cited by 129
Sunaga, N., Oriuchi, N., Kaira, K., Yanagitani, N., Tomizawa, Y., Hisada, T., Ishizuka, T., Endo, K., & Mori, M. (2007) · Lung Cancer · doi:10.1016/j.lungcan.2007.08.012 · Cited by 122
Roengvoraphoj, M., Tsongalis, G. J., Dragnev, K. H., & Rigas, J. R. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.05.001 · Cited by 121
Janjigian, Y. Y., McDonnell, K., Kris, M. G., Shen, R., Sima, C. S., Bach, P. B., Rizvi, N. A., & Riely, G. J. (2009) · Cancer · doi:10.1002/cncr.24813 · Cited by 120
Impact of EGFR mutation analysis in non-small cell lung cancer
Yamamoto, H., Toyooka, S., & Mitsudomi, T. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2008.06.021 · Cited by 116
Kobayashi, K., & Hagiwara, K. (2013) · Targeted Oncology · doi:10.1007/s11523-013-0258-9 · Cited by 110
Self-citationTreating Patients With EGFR-Sensitizing Mutations: First Line or Second Line—Is There a Difference?
Mok, T., Yang, J.-J., & Lam, K.-C. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.0652 · Cited by 103
Tanaka, T., Nagai, Y., Miyazawa, H., Koyama, N., Matsuoka, S., Sutani, A., Huqun, Udagawa, K., Murayama, Y., Nagata, M., et al. (2006) · Cancer Science · doi:10.1111/j.1349-7006.2006.00377.x · Cited by 101
Self-citationOizumi, S., Kobayashi, K., Inoue, A., Maemondo, M., Sugawara, S., Yoshizawa, H., Isobe, H., Harada, M., Kinoshita, I., Okinaga, S., et al. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0426 · Cited by 101
Self-citationGaughan, E. M., & Costa, D. B. (2011) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834010397569 · Cited by 104
Azzoli, C. G., Giaccone, G., & Temin, S. (2010) · Journal of Oncology Practice · doi:10.1200/jop.091065 · Cited by 96
Suh, C. H., Park, H. S., Kim, K. W., Pyo, J., Hatabu, H., & Nishino, M. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.06.032 · Cited by 97
Degenhardt, Y., Greshock, J. D., Laquerre, S. G., Gilmartin, A. G., Jing, J., Richter, M. C., Zhang, X., Bleam, M. R., Halsey, W. S., Hughes, A., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0095 · Cited by 93
Sugio, K., Uramoto, H., Onitsuka, T., Mizukami, M., Ichiki, Y., Sugaya, M., Yasuda, M., Takenoyama, M., Oyama, T., Hanagiri, T., et al. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2008.09.010 · Cited by 89
Targeting epidermal growth factor receptor: Central signaling kinase in lung cancer
Yoshida, T., Zhang, G., & Haura, E. B. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.05.014 · Cited by 92
Epidermal growth factor receptor in relation to tumor development: EGFR‐targeted anticancer therapy
Okamoto, I. (2009) · FEBS Journal · doi:10.1111/j.1742-4658.2009.07449.x · Cited by 81
Miyazawa, H., Tanaka, T., Nagai, Y., Matsuoka, M., Huqun, Sutani, A., Udagawa, K., Zhang, J., Hirama, T., Murayama, Y., et al. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2007.00706.x · Cited by 79
Self-citationJu, L., Zhou, C., Li, W., & Yan, L. (2010) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22888 · Cited by 75
EGFR expression and gene copy number in triple-negative breast carcinoma
Gümüşkaya, B., Alper, M., Hücümenoğlu, S., Altundağ, K., Üner, A., & Güler, G. (2010) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2010.07.118 · Cited by 70
Yoshioka, H., Hotta, K., Kiura, K., Takigawa, N., Hayashi, H., Harita, S., Kuyama, S., Segawa, Y., Kamei, H., Umemura, S., et al. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181c20063 · Cited by 67
Yoda, S., Dagogo‐Jack, I., & Hata, A. N. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.08.007 · Cited by 68
Okamoto, I., Takahashi, T., Okamoto, H., Nakagawa, K., Watanabe, K., Nakamatsu, K., Nishimura, Y., Fukuoka, M., & Yamamoto, N. (2010) · Lung Cancer · doi:10.1016/j.lungcan.2010.08.016 · Cited by 61
Beau‐Faller, M., Legrain, M., Voegeli, A.-C., Guérin, É., Lavaux, T., Ruppert, A.-M., Neuville, A., Massard, G., Wihlm, J.-M., Quoix, É., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604925 · Cited by 59
Biomarkers That Currently Affect Clinical Practice: EGFR, ALK, MET, KRAS
Vincent, M. D., Kuruvilla, M. S., Leighl, N. B., & Kamel‐Reid, S. (2012) · Current Oncology · doi:10.3747/co.19.1149 · Cited by 56
Gefitinib for the treatment of non-small-cell lung cancer
Hida, T., Ogawa, S., Park, J. C., Park, J. Y., Shimizu, J., Horio, Y., & Yoshida, K. (2008) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.9.1.17 · Cited by 58
Naoki, K., Soejima, K., Okamoto, H., Hamamoto, J., Hida, N., Nakachi, I., Yasuda, H., Nakayama, S., Yoda, S., Satomi, R., et al. (2011) · International Journal of Clinical Oncology · doi:10.1007/s10147-011-0187-5 · Cited by 54
Personalized Medicine for Targeted and Platinum-Based Chemotherapy of Lung and Bladder Cancer
Cimino, G. D., Pan, C.-X., & Henderson, P. T. (2013) · Bioanalysis · doi:10.4155/bio.12.325 · Cited by 58
First-line treatment of EGFR-mutated nonsmall cell lung cancer: critical review on study methodology
Sebastian, M., Schmittel, A. H., & Reck, M. (2014) · European Respiratory Review · doi:10.1183/09059180.00008413 · Cited by 54
Locked nucleic acid (LNA): A modern approach to cancer diagnosis and treatment
Kamali, M. J., Salehi, M., Fatemi, S., Moradi, F., Khoshghiafeh, A., & Ahmadifard, M. (2022) · Experimental Cell Research · doi:10.1016/j.yexcr.2022.113442 · Cited by 56
Wu, M., Zhao, J., Song, S. W., Zhuo, M., Wang, X., Bai, H., Wang, S., Yang, L., An, T., Zhang, Y., et al. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2009.04.011 · Cited by 51
Takamochi, K., Suzuki, K. Z., Sugimura, H., Funai, K., Mori, H., Bashar, A. H. M., & Kazui, T. (2007) · Lung Cancer · doi:10.1016/j.lungcan.2007.04.016 · Cited by 51
Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC)
Tiseo, M. (2010) · Drug Design Development and Therapy · doi:10.2147/dddt.s6594 · Cited by 51
Fool’s gold, lost treasures, and the randomized clinical trial
Stewart, D. J., & Kurzrock, R. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-193 · Cited by 51
EGFR tyrosine kinase inhibitors for the treatment of NSCLC in East Asia: present and future
Yang, C.-H. (2008) · Lung Cancer · doi:10.1016/s0169-5002(08)70102-8 · Cited by 47
EGFR FISH versus mutation: Different tests, different end-points
Cappuzzo, F. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2008.02.008 · Cited by 49
Karlsen, E., Kahler, S. L., Tefay, J., Joseph, S. R., & Simpson, F. (2021) · Cells · doi:10.3390/cells10051206 · Cited by 52
Wang, H., Huang, J., Yu, X., Han, S., Yan, X., Sun, S., & Zhu, X. (2014) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1709-0 · Cited by 47
The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer
Metro, G., & Crinò, L. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.11.34 · Cited by 45
Molecular Analysis-Based Treatment Strategies for the Management of Non-small Cell Lung Cancer
West, H., Lilenbaum, R., Harpole, D. H., Wozniak, A. J., & Sequist, L. V. D. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181b27170 · Cited by 44
Xu, J., Han, Y., Duan, H. Q., Gao, E., Zhang, Y., Liu, X., Zhang, J. S., Toschi, L., Galetta, D., Azzariti, A., et al. (2008) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-008-0512-1 · Cited by 42
Hagiwara, K., & Kobayashi, K. (2012) · Cancer Science · doi:10.1111/cas.12081 · Cited by 42
Self-citationJu, L., & Zhou, C. (2013) · Cancer Cell International · doi:10.1186/1475-2867-13-15 · Cited by 40
Yamauchi, Y., Izumi, Y., Yamamoto, J., & Nomori, H. (2013) · Phytotherapy Research · doi:10.1002/ptr.5056 · Cited by 39
Salto‐Tellez, M., Tsao, M., Shih, J., Thongprasert, S., Lü, S., Chang, G., Au, J. S. K., Chou, T., Lee, J. S., Shi, Y.-K., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318227816a · Cited by 38
Genetic profiling and epidermal growth factor receptor-directed therapy in nonsmall cell lung cancer
Cadranel, J. L., Zalcman, G., & Sequist, L. V. D. (2010) · European Respiratory Journal · doi:10.1183/09031936.00179409 · Cited by 39
Pooled analysis of clinical outcome for EGFR TKI ‐treated patients with EGFR mutation‐positive NSCLC
Paz-Ares, L. G., Soulières, D., Moecks, J., Bāra, I., Mok, T. S. K., & Klughammer, B. (2014) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12278 · Cited by 38
Fukui, T., & Mitsudomi, T. (2008) · General Thoracic and Cardiovascular Surgery · doi:10.1007/s11748-007-0193-8 · Cited by 38
Okamoto, I., Mitsudomi, T., Nakagawa, K., & Fukuoka, M. (2010) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834010370698 · Cited by 37
Morinaga, R., Okamoto, I., Fujita, Y., Arao, T., Sekijima, M., Nishio, K., Ito, H., Fukuoka, M., Kadota, J., & Nakagawa, K. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00962.x · Cited by 37
Gefitinib in Non Small Cell Lung Cancer
Costanzo, R., Piccirillo, M. C., Sandomenico, C., Carillio, G., Montanino, A., Daniele, G., Giordano, P., Bryce, J., Feo, G. D., Maïo, M. D., et al. (2011) · BioMed Research International · doi:10.1155/2011/815269 · Cited by 37
Masago, K., Fujita, S., Hatachi, Y., Fukuhara, A., Sakuma, K., Ichikawa, M., Kim, Y. H., Mio, T., & Mishima, M. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00931.x · Cited by 36
The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC: Figure 1
Gately, K. A., O’Flaherty, J. D., Cappuzzo, F., Pirker, R., Kerr, K. M., & O'Byrne, K. J. (2011) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2011-200275 · Cited by 35
Azuma, K., Okamoto, I., Kawahara, A., Taira, T., Nakashima, K., Hattori, S., Kinoshita, T., Takeda, M., Nakagawa, K., Takamori, S., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31822eeba2 · Cited by 32
Usui, K., Ushijima, T., Tanaka, Y., Tanai, C., Noda, H., Abe, N., Horiuchi, H., & Ishihara, T. (2011) · Pulmonary Medicine · doi:10.1155/2011/290132 · Cited by 31
Lee, D., Suh, Y., Kang, S. Y., Park, T. I., Jeong, J. Y., & Kim, S. H. (2012) · Brain Pathology · doi:10.1111/bpa.12000 · Cited by 30
Somatic pharmacogenomics in cancer
Ikediobi, O. N. (2008) · The Pharmacogenomics Journal · doi:10.1038/tpj.2008.8 · Cited by 29
Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer
Asami, K. (2014) · World Journal of Clinical Oncology · doi:10.5306/wjco.v5.i4.646 · Cited by 25
Joensuu, G., Joensuu, T. K., Nokisalmi, P., Reddy, C. A., Isola, J. J., Ruutu, M. L., Kouri, M., Kupelian, P. A., Collan, J., Pesonen, S. A., et al. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.07.1731 · Cited by 26
Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive
Santarpía, M., Altavilla, G., Salazar, M., Magrí, I., Pettineo, G., Benecchi, S., & Rosell, R. (2011) · Expert Review of Respiratory Medicine · doi:10.1586/ers.11.27 · Cited by 24
Gefitinib for the treatment of non-small-cell lung cancer
Campbell, L., Blackhall, F. H., & Thatcher, N. J. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.481283 · Cited by 25
Singh, N., Bal, A., Aggarwal, A. N., Das, A., & Behera, D. (2010) · Future Oncology · doi:10.2217/fon.10.30 · Cited by 24
Ellis, P. M., Morzycki, W., Melosky, B. L., Butts, C., Hirsh, V., Krasnoshtein, F., Murray, N., Shepherd, F. A., Soulières, D., Tsao, M., et al. (2009) · Current Oncology · doi:10.3747/co.v16i1.393 · Cited by 24
Schettino, C., Bareschino, M. A., Maione, P., Rossi, A., Ciardiello, F., & Gridelli, C. (2008) · Current Genomics · doi:10.2174/138920208784533665 · Cited by 24
Zhu, Y., Guo, Z., Liu, Y., Zheng, X., Yang, G., & Zheng, G. (2017) · Oncology Letters · doi:10.3892/ol.2017.7679 · Cited by 22
Tian, Y., Zhao, J., Ren, P., Wang, B., Zhao, C., Shi, C., Wei, B., Ma, J., & Guo, Y. (2018) · PLoS ONE · doi:10.1371/journal.pone.0201682 · Cited by 22
Wei, W., Mao, N., Ning, S., Li, J., Liu, H., Xie, T., Zhong, J., Feng, Y., Wei, C., & Zhang, L. (2016) · PLoS ONE · doi:10.1371/journal.pone.0168795 · Cited by 22
Wang, Z., Fang, S., Guo, J., Liu, J., Li, C., Liu, L., Shi, H., Liu, L., Li, H., Xie, C. L., et al. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s63665 · Cited by 21
Metadata
- Authors
- Sutani, A., Nagai, Y., Udagawa, K., Uchida, Y., Koyama, N., Murayama, Y., Tanaka, T., Miyazawa, H., Nagata, M., Kanazawa, M., Hagiwara, K., & Kobayashi, K.
- Affiliations
- Saitama Medical University (JP)
- Corresponding author
- Kobayashi, K
- Venue
- British Journal of Cancer
- Published
- 2006-11-14
- Volume
- 95
- Issue
- 11
- Pages
- 1483-1489
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- PMC
- PMC2360739
- OpenAlex
- W2069312070
- Cited by
- 167
- References
- 20
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 2 · 2023: 2 · 2022: 2 · 2021: 1 · 2019: 2 · 2018: 5 · 2017: 5 · 2016: 1 · 2015: 7 · 2014: 11 · 2013: 16 · 2012: 15
- FWCI
- 14.78
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- www.springer.com/tdm (unspecified)
- Locations
- British Journal of Cancer (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- American Society of Clinical Oncology
- Ministry of Education, Culture, Sports, Science and Technology
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- gefitinib, non-small cell lung cancer, EGFR mutation, targeted therapy, second-line chemotherapy, response rate, survival, prognostic factors, hepatotoxicity, skin toxicity
- MeSH terms
- Gefitinib, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, DNA Mutational Analysis, Female, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Prognosis, Quinazolines, Survival Analysis, Polymerase Chain Reaction, Genes, erbB-1, Drug Resistance, Neoplasm, Peptide Nucleic Acids
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
